// App-Quantinova.ai

55 : Can interleukin IL-17A levels predict response to biologic treatment in patients with rheumatoid arthritis?

Researchers

Presenter

  • Stephen McDonald

Principal Investigators

  • Rachel Reed

  • Ivona Baricevic-Jones

  • Stephanie Ling

  • Darren Plant

  • Anne Barton

Medical Centers

  • NIHR Manchester BRC, University of Manchester, Manchester, UNITED KINGDOM

  • The Kellgren Centre, Manchester University Foundation Trust, Manchester, UNITED KINGDOM

  • Manchester Molecular Pathology Innovation Centre, University of Manchester, Manchester, UNITED KINGDOM

  • Stoller Biomarker Discovery Centre, University of Manchester, Manchester, UNITED KINGDOM

  • Division of Musculoskeletal & Dermatological Sciences, Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Interleukin 17A

Drug/Treatment

  • Interleukin

  • Adalimumab

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved